Eric Tartour

List of Publications by Year
in descending order

194 papers	17,220 citations	15504 65 h-index	16183 124 g-index
212 all docs	212 docs citations	212 times ranked	23451 citing authors

#	Article	IF	Citations
1	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. Journal of Experimental Medicine, 2015, 212, 139-148.	8.5	836
2	Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures. Journal of Clinical Oncology, 2008, 26, 4410-4417.	1.6	797
3	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
4	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
5	PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. Cancer Research, 2013, 73, 128-138.	0.9	554
6	VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. Cancer Research, 2013, 73, 539-549.	0.9	528
7	Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clinical Cancer Research, 2006, 12, 465-472.	7.0	517
8	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
9	Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report: Figure 1. European Heart Journal, 2015, 36, 2011-2017.	2.2	383
10	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. Cancer Research, 2011, 71, 5601-5605.	0.9	341
11	Transplantation of Human Embryonic Stem Cell–Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2018, 71, 429-438.	2.8	336
12	Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism. Blood, 2002, 99, 2114-2121.	1.4	309
13	IL-18 Induces PD-1–Dependent Immunosuppression in Cancer. Cancer Research, 2011, 71, 5393-5399.	0.9	307
14	Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews, 2011, 30, 83-95.	5.9	275
15	Control of the Immune Response by Pro-Angiogenic Factors. Frontiers in Oncology, 2014, 4, 70.	2.8	260
16	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2017, 2, e000213.	4.5	248
17	A meta-analysis of the anterior cingulate contribution to social pain. Social Cognitive and Affective Neuroscience, 2015, 10, 19-27.	3.0	247
18	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	4.6	237

#	Article	IF	Citations
19	Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nature Communications, 2017, 8, 15221.	12.8	231
20	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	4.6	223
21	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	4.6	203
22	Mucosal Imprinting of Vaccine-Induced CD8^{+} T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine, 2013, 5, 172ra20.	12.4	195
23	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology, 2012, 1, 894-907.	4.6	194
24	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. Current Topics in Microbiology and Immunology, 2010, 344, 1-24.	1.1	193
25	Resident memory T cells, critical components in tumor immunology. , 2018, 6, 87.		193
26	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
27	A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy, 2010, 33, 991-998.	2.4	188
28	A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 735-744.	1.1	187
29	Trial Watch. OncoImmunology, 2012, 1, 699-739.	4.6	184
30	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research, 2017, 77, 1075-1082.	0.9	166
31	Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. Journal of Gene Medicine, 2003, 5, 690-699.	2.8	164
32	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	4.6	152
33	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150
34	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 2011, 118, 4853-4862.	1.4	144
35	The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens. Journal of Immunology, 2000, 165, 3301-3308.	0.8	132
36	Trial watch. OncoImmunology, 2013, 2, e23082.	4.6	130

#	Article	IF	Citations
37	Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer. Journal of Immunotherapy, 2000, 23, 570-580.	2.4	123
38	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clinical Microbiology and Infection, 2022, 28, 163-177.	6.0	120
39	Consensus nomenclature for CD8$^+$ T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
40	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	4.6	110
41	Colorectal cancer and immunity: What we know and perspectives. World Journal of Gastroenterology, 2014, 20, 3738.	3.3	105
42	Trial watch. OncoImmunology, 2012, 1, 179-188.	4.6	104
43	Expression and activity of IL-17 in cutaneous T-cell lymphomas(mycosis fungoides and sezary) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	5.1	103
44	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	4.6	103
45	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	4.6	102
46	Variable expression of CD3-Î¶ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with til phenotype and function. International Journal of Cancer, 1995, 63, 205-212.	5.1	101
47	Trial Watch. OncoImmunology, 2013, 2, e26621.	4.6	101
48	A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. Journal of Immunological Methods, 2003, 283, 91-98.	1.4	98
49	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clinical Cancer Research, 2012, 18, 2943-2953.	7.0	97
50	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	4.6	97
51	A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology, Immunotherapy, 2011, 60, 261-271.	4.2	95
52	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology, 2012, 1, 326-333.	4.6	95
53	Cancer-Induced Immunosuppression: IL-18â€"Elicited Immunoablative NK Cells. Cancer Research, 2012, 72, 2757-2767.	0.9	95
54	Modulation of Immunity by Antiangiogenic Molecules in Cancer. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	94

#	Article	IF	Citations
55	Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. European Journal of Immunology, 1998, 28, 2726-2737.	2.9	86
56	Trial Watch. OncoImmunology, 2012, 1, 493-506.	4.6	86
57	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?. Cancers, 2019, 11, 283.	3.7	86
58	PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infectious Diseases, The, 2020, 20, 585-597.	9.1	84
59	Trial Watch. OncoImmunology, 2013, 2, e25595.	4.6	83
60	Prognostic Value of Intratumoral Interferon Gamma Messenger RNA Expression in Invasive Cervical Carcinomas. Journal of the National Cancer Institute, 1998, 90, 287-294.	6.3	80
61	The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. European Journal of Immunology, 2006, 36, 1124-1135.	2.9	80
62	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
63	Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Molecular Cancer Therapeutics, 2015, 14, 1336-1345.	4.1	77
64	The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer. Cancer Research, 2008, 68, 3907-3914.	0.9	75
65	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer, 2020, 23, 73-81.	5.3	75
66	Decreased frequency of HLA-DRB 1*13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. , 1996, 69, 159-164.		74
67	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
68	Trial Watch. OncoImmunology, 2012, 1, 306-315.	4.6	70
69	Lung cancer: potential targets for immunotherapy. Lancet Respiratory Medicine, the, 2013, 1, 551-563.	10.7	69
70	Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients. Journal of Immunotherapy, 2008, 31, 101-112.	2.4	65
71	HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers. International Journal of Cancer, 2020, 147, 1222-1227.	5.1	65
72	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64

#	Article	IF	Citations
73	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines, 2016, 4, 37.	4.4	63
74	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
75	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	4.6	62
76	The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. International Immunology, 2003, 15, 1161-1171.	4.0	59
77	Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities. Cancer Research, 2008, 68, 3931-3940.	0.9	58
78	Trial Watch. OncoImmunology, 2013, 2, e24238.	4.6	58
79	Therapeutic cancer vaccine: building the future from lessons of the past. Seminars in Immunopathology, 2019, 41, 69-85.	6.1	56
80	B Subunit of Shiga Toxin-Based Vaccines Synergize with Î±-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity. Journal of Immunology, 2007, 179, 3371-3379.	0.8	55
81	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research, 2012, 18, 6284-6295.	7.0	54
82	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
83	Targeting Resident Memory T Cells for Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1722.	4.8	51
84	Better understanding tumorâ€"host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head and Neck, 2010, 32, 946-958.	2.0	50
85	1st Class Ticket to Class I: Protein Toxins as Pathfinders for Antigen Presentation. Traffic, 2002, 3, 697-704.	2.7	49
86	Mucosal vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 2175-2187.	3.3	49
87	Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget, 2015, 6, 27832-27846.	1.8	46
88	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	4.6	46
89	Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses. Clinical Cancer Research, 2006, 12, 3158-3167.	7.0	44
90	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	5.1	44

#	Article	IF	Citations
91	Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. Cancer, 1993, 72, 3296-3303.	4.1	43
92	IL-6 is a survival prognostic factor in renal cell carcinoma. Immunology Letters, 1997, 58, 121-124.	2.5	43
93	IL-15 *Trans*-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. Journal of Immunology, 2016, 197, 168-178.	0.8	43
94	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.9	42
95	CXCR6 deficiency impairs cancer vaccine efficacy and CD8[+] resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41
96	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	4.6	40
97	Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients. Journal of Immunology, 2008, 181, 431-439.	0.8	37
98	Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer. Journal of Clinical Oncology, 2009, 27, e5-e6.	1.6	36
99	Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends in Pharmacological Sciences, 2014, 35, 163-165.	8.7	36
100	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	5.8	35
101	VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. OncoImmunology, 2013, 2, e25156.	4.6	32
102	Control of the Adaptive Immune Response by Tumor Vasculature. Frontiers in Oncology, 2014, 4, 61.	2.8	32
103	Trial Watch. OncoImmunology, 2014, 3, e28344.	4.6	31
104	Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf cohort of 348 French squamous cell carcinomas. Human Pathology, 2018, 78, 63-71.	2.0	31
105	Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood, 2010, 115, 3025-3032.	1.4	30
106	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. Journal of Immunology, 2010, 185, 418-423.	0.8	30
107	Sunitinib in kidney cancer: 10 years of experience and development. Expert Review of Anticancer Therapy, 2017, 17, 129-142.	2.4	30
108	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	4.6	29

#	Article	IF	Citations
109	Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 871-882.	4.2	29
110	Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Therapy, 1999, 6, 271-281.	4.6	28
111	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. OncoImmunology, 2017, 6, e1286437.	4.6	28
112	In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). British Journal of Haematology, 1998, 100, 550-556.	2.5	27
113	Control of tumor development by intratumoral cytokines. Immunology Letters, 1999, 68, 135-139.	2.5	27
114	Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Research, 2008, 18, 104-111.	1.2	27
115	Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 467-473.e2.	0.8	27
116	Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy, 2014, 16, 427-439.	0.7	27
117	Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines. Clinical Cancer Research, 2016, 22, 530-532.	7.0	27
118	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	4.6	26
119	The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments. Head and Neck Pathology, 2020, 14, 330-340.	2.6	26
120	Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (FcγR) encoded by an alternatively spliced transcript of the FcγRII gene. International Immunology, 1993, 5, 859-868.	4.0	25
121	Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma. , 1997, 79, 1401-1408.		25
122	Characterization of immune functions in TRAF4–deficient mice. Immunology, 2008, 124, 562-574.	4.4	25
123	Soluble FcγR (sFcγR): Detection in Biological Fluids and Production of a Murine Recombinant sFcγR Biologically Active in vitro and in vivo. Immunobiology, 1992, 185, 207-221.	1.9	23
124	Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Human Immunology, 2004, 65, 1307-1318.	2.4	23
125	Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors. Journal of Controlled Release, 2016, 239, 82-91.	9.9	23
126	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. OncoImmunology, 2015, 4, e1001236.	4.6	22

#	Article	IF	Citations
127	Editorial: Tissue Resident Memory T Cells. Frontiers in Immunology, 2019, 10, 1018.	4.8	22
128	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Advances, 2021, 5, 1816-1829.	5.2	22
129	Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset. Vaccine, 2011, 29, 5892-5903.	3.8	21
130	Following up tumor-specific regulatory T cells in cancer patients. OncoImmunology, 2013, 2, e25444.	4.6	21
131	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4$^+$Th1 responses against telomerase in cancer patients. OncoImmunology, 2016, 5, e1137416.	4.6	21
132	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nature Communications, 2018, 9, 5097.	12.8	21
133	Dendritic cell-induced apoptosis of human cytomegalovirus-infected fibroblasts promotes cross-presentation of pp65 to CD8+ T cells. Journal of General Virology, 2008, 89, 78-86.	2.9	20
134	Arginine administration to critically ill patients with a low nitric oxide fraction in the airways: a pilot study. Intensive Care Medicine, 2013, 39, 1663-1665.	8.2	20
135	Inhibition of the Differentiation of Monocyte-Derived Dendritic Cells by Human Gingival Fibroblasts. PLoS ONE, 2013, 8, e70937.	2.5	19
136	A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice. Clinical Cancer Research, 2016, 22, 4133-4144.	7.0	19
137	High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes. Frontiers in Oncology, 2018, 8, 517.	2.8	19
138	Efficacy of DNA Vaccines Forming E7 Recombinant Retroviral Virus-Like Particles for the Treatment of Human Papillomavirus-Induced Cancers. Human Gene Therapy, 2013, 24, 533-544.	2.7	18
139	Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Human Vaccines and Immunotherapeutics, 2014, 10, 104-113.	3.3	17
140	Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells. BMC Cancer, 2013, 13, 592.	2.6	16
141	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer, 2018, 143, 3008-3018.	5.1	16
142	A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response. Current Gene Therapy, 2014, 14, 236-246.	2.0	16
143	Early Impairment of CD8+T Cells Immune Response Against Epstein–Barr Virus (EBV) Antigens Associated with High Level of Circulating Mononuclear EBV DNA Load in HIV Infection. Journal of Clinical Immunology, 2004, 24, 125-134.	3.8	15
144	Retrograde transport is not required for cytosolic translocation of the B-subunit of Shiga toxin. Journal of Cell Science, 2015, 128, 2373-2387.	2.0	15

#	Article	IF	Citations
145	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. Clinical Cancer Research, 2018, 24, 5534-5542.	7.0	15
146	Cytokines and cell regulation. Molecular Aspects of Medicine, 1997, 18, 1-90.	6.4	14
147	NK cells from pleural effusions are potent antitumor effector cells. European Journal of Immunology, 2013, 43, 331-334.	2.9	14
148	The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. Journal of Immunology, 2015, 195, 1891-1901.	0.8	14
149	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1^{+} Tim-3^{+} CD8^{+} T Cells. Journal of Visualized Experiments, 2018, , .	0.3	14
150	A French cohort for assessing COVID-19 vaccine responses in specific populations. Nature Medicine, 2021, 27, 1319-1321.	30.7	14
151	Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. OncoImmunology, 2016, 5, e1164363.	4.6	13
152	HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Modern Pathology, 2018, 31, 1645-1652.	5.5	13
153	Defective IL2 Gene Expression in Newborn is Accompanied with Impaired Tyrosine-Phosphorylation in T Cells. Pediatric Research, 1999, 45, 409-413.	2.3	13
154	An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: Case report and review of literature. Journal of Clinical Virology, 2012, 54, 190-193.	3.1	12
155	Immunotherapy of HPV-associated head and neck cancer. OncoImmunology, 2013, 2, e24534.	4.6	12
156	Smoking and the Association Between Depressive Symptoms and Absolute Neutrophil Count in the Investigations Préventives et Cliniques Cohort Study. Psychosomatic Medicine, 2015, 77, 1039-1049.	2.0	12
157	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Review of Anticancer Therapy, 2014, 14, 523-542.	2.4	11
158	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large MulticenterÂStudy. Clinical Genitourinary Cancer, 2017, 15, e469-e476.	1.9	11
159	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. Immunology Letters, 2000, 75, 1-8.	2.5	10
160	Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines. OncoImmunology, 2017, 6, e1358841.	4.6	10
161	Suppression by Thimerosal of Ex-Vivo CD4+ T Cell Response to Influenza Vaccine and Induction of Apoptosis in Primary Memory T Cells. PLoS ONE, 2014, 9, e92705.	2.5	10
162	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	9.4	10

#	Article	IF	Citations
163	STxB as an Antigen Delivery Tool for Mucosal Vaccination. Toxins, 2022, 14, 202.	3.4	10
164	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	4.8	9
165	Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of Transcription of HPV E6 and E7. Cancers, 2020, 12, 2836.	3.7	9
166	Fluorospot Assay: Methodological Analysis. , 2005, 302, 289-296.		8
167	Immunity and squamous cell carcinoma of the anus: Epidemiological, clinical and therapeutic aspects. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 18-23.	1.5	8
168	Regulation of CD44 Isoform Expression and CD44-Mediated Signaling in Human Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 83-90.	1.6	8
169	Murine soluble FcÎ³ receptors/IgG-binding factors (IgG-BF): Analysis of the relation to FcÎ³RII and production of milligram quantities of biologically active recombinant IgG-BF. Immunologic Research, 1992, 11, 181-190.	2.9	7
170	Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS ONE, 2017, 12, e0181403.	2.5	7
171	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Cells, 2022, 11, 17.	4.1	7
172	A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project. Nature Medicine, 2022, 28, 882-884.	30.7	7
173	Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells. Journal of Immunological Methods, 1999, 227, 149-160.	1.4	6
174	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. Cancers, 2021, 13, 5562.	3.7	6
175	The adjuvant effect of melanin is superior to incomplete Freundâ€™s adjuvant in subunit/peptide vaccines in mice. Cancer Immunology, Immunotherapy, 2020, 69, 2501-2512.	4.2	5
176	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, 701273.	4.8	5
177	An allogeneic NK cell line engineered to express chimeric antigen receptors. OncoImmunology, 2013, 2, e27156.	4.6	4
178	Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	4
179	In Silico Adjuvant Design and Validation. Methods in Molecular Biology, 2017, 1494, 107-125.	0.9	4
180	Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis. Journal of Visualized Experiments, 2019, , .	0.3	4

#	Article	IF	Citations
181	Correlation between Shiga toxin Bâ€subunit stability and antigen crosspresentation: A mutational analysis. FEBS Letters, 2008, 582, 185-189.	2.8	3
182	Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine. Clinical Cancer Research, 2016, 22, 2317-2319.	7.0	3
183	Immune therapy in colorectal cancer. Colorectal Cancer, 2017, 6, 1-10.	0.8	3
184	Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens. Vaccines, 2021, 9, 1412.	4.4	3
185	Phenotypic and Functional Analysis of Tumour-Infiltrating Lymphocytes from Patients with Renal Cell Carcinoma. European Urology, 1994, 25, 151-157.	1.9	2
186	Correspondence to Creydt VP et al., Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells, Microbes Infect. 8(2) (2006) 410â€"419. Microbes and Infection, 2006, 8, 2331-2332.	1.9	2
187	New therapeutic targets in the inflammatory microenvironment. ESMO Open, 2018, 3, e000310.	4.5	2
188	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
189	Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 2523-2523.	1.6	2
190	IMMUNOTHÃ‰RAPIE DES CANCERS. Bulletin De L'Academie Veterinaire De France, 2009, , 363.	0.0	0
191	Le papillomavirus nâ€™attaque pas que les femmes. Revue Francophone Des Laboratoires, 2013, 2013, 50-53.	0.0	0
192	Abstract 752: A CCR4 antagonist combined with protein-or DNA-based vaccines efficiently breaks tolerance and elicits CD8+T cells directed against self and viral associated tumor antigens. , 2011, , .		0
193	Abstract 5388: Local mucosal CD8+T cell response is required to inhibit the growth of orthotopic head and neck and lung cancers. , 2012, , .		0
194	Abstract 3315: Synergistic direct and distant bystander effects contribute to the efficiency of a new suicide gene therapy against cancer.. , 2013, , .		0